Gilead Publishes Its 2014 Corporate Contributions Report
Foster City, CA, August 12, 2015 – Gilead Sciences, Inc. today announced that it issued its first Corporate Contributions Report, which provides an overview of the support the company offers to organizations around the world that are working to improve the lives of people with life-threatening diseases.
“We are inspired by the dedication of the organizations we support, as they continue to help patients and communities overcome barriers to accessing healthcare,” said Gregg Alton, Executive Vice President, Corporate and Medical Affairs, Gilead Sciences. “Through our corporate giving initiatives, we are able to support efforts to increase disease awareness, expand professional education, and improve diagnosis and linkage to care for millions of people around the world.”
In 2014, Gilead donated $280 million across 1,200 organizations whose work is focused on the following three areas:
Reducing Health Disparities
In 2014, Gilead contributed funding to efforts that support underserved communities, which have systematically experienced greater social or economic obstacles to accessing health services. The goal of these initiatives is to help equalize healthcare opportunities around the world in order to achieve the best possible health outcomes. These programs include initiatives to increase education about HIV, including advancing education about HIV pre-exposure prophylaxis, or PrEP, and offer free hepatitis B and C screenings to Vietnamese Americans who are often isolated by language and cultural barriers.
“As a non-profit that is not funded by the Government, we rely on the generous support of the community and funders like Gilead who really care about the underserved,” said Becky Nguyen, Executive Director of Vietnamese American Cancer Foundation.
This report highlights the progress made in improving worldwide access to medicines through the company’s patient assistance programs, tiered-pricing model and contributions to the Medicines Patent Pool. Today, more than 7 million people in the developing world are receiving Gilead antiretroviral therapy, up from 30,000 in 2006.
In addition, Gilead launched the Frontlines of Communities in the United States (FOCUS) program in 2010 to address barriers to routine HIV screening and access to care. Since 2010, more than 1.5 million people throughout the United States have been tested for HIV through FOCUS, which is now being expanded to include HCV testing.
Education is key to disease prevention and to long-term disease management. The company assists community organizations by supporting disease awareness programs for patients and expanding knowledge and skills for healthcare professionals. The report offers information about the various ways Gilead supports advancing education initiatives, including continuing medical education programs, and community and patient outreach efforts that help empower patients to educate others in their communities.
To view Gilead’s 2014 Corporate Contributions Report or to learn more about Gilead’s corporate contributions program, visit www.molu16.icu.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. We strive to transform and simplify care for people with life-threatening illnesses around the world, always keeping the patients and the communities we serve at the forefront.